Multiple-Ascending Dose in Japanese Patients Bridging Study

A Randomized, Double-Blinded, Placebo-Controlled, MultipleAscending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rodatristat Ethyl in Healthy Japanese and Caucasian Subjects

This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Rodatristat Ethyl 300 mg BID; Drug: Placebo; Drug: Rodatristat Ethyl 600 mg BID

Detailed Description

This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects. Two dose levels of rodatristat ethyl, 300 mg twice daily (BID) and 600 mg BID multiple doses (with a single dose lead in), will be explored in an ascending dose fashion with a safety review in between (Figure 1 below). Approximately 48 subjects will be enrolled in 4 cohorts.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Glendale, California, United States, 91206
      • California Clinical Trials Medical Group (CCTMG)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy males or females aged 18 to 55 years, inclusive
• A male subject is eligible to participate if he does not have a female partner who is pregnant or who intends to become pregnant during the study. Male subjects must agree to use contraception starting at Screening, during the treatment period, and for at least 100 days after the last dose of Investigational Product (IP), and refrain from donating sperm during this period.
• Female subjects of childbearing potential must agree to use contraception starting at Screening, during the treatment period, and for at least 30 days after the last dose of IP.
• Body mass index (BMI) ≥ 18 kg/m2 and ≤ 32 kg/m2 at Screening
• Japanese subjects must have been born in Japan and not have lived outside of Japan > 10 years at the time of Screening, have both parents and grandparents of ethnic Japanese origin, and have not significantly modified their diets since leaving Japan.
• Caucasian subjects must be of European or Latin American descent (i.e., White).
• Capable of giving signed informed consent, able to understand and comply with protocol requirements, instructions, and protocol related restrictions, and likely to complete the study as planned.

Exclusion Criteria:

• Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, or cardiovascular disease
• a. History of Gilbert's Syndrome
• b. History of depression
• c. History of any allergy that, in the opinion of the Investigator, contraindicates participation in the trial
• Any positive finding on the Columbia-Suicide Severity Rating Scale (C-SSRS).
• Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to Day 1
• Participation in an investigational drug, vaccine, or device study within 30 days before IP administration or 90 days for a biologic study
• Evidence of previous myocardial infarction
• a. Any conduction abnormality (including but not specific to atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome [unless curative ablation treatment]).
• b. Sinus pauses > 3 seconds.
• c. Any significant arrhythmia which, in the opinion of the Investigator and Medical Monitor, will interfere with the safety for the individual subject.
• d. Non-sustained or sustained ventricular tachycardia (≥ 3 consecutive ventricular ectopic beats).
• Abnormal blood pressure, either low (defined as < 90 mmHg systolic and/or < 50 mmHg diastolic) or high (defined as > 140 mmHg systolic and/or > 90 mmHg diastolic)
• Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, coagulation, chemistry panel, and urinalysis)
• a. Positive serology for hepatitis B, hepatitis C virus, or human immunodeficiency virus
• b. Estimated glomerular filtration rate < 80 mL/min/1.73 m2
• c. Aspartate aminotransferase, alanine aminotransferase values greater than 1.5 x upper limit of normal.
• d. Positive urine test for drugs of abuse
• e. Positive alcohol test (breath, saliva, or urine)
• Use of prescription or nonprescription drugs including high dose vitamins, dietary supplements (including St. John's Wort) within 7 days or 5 half-lives of the prescription or nonprescription drug (whichever was longer) prior to the first dose of IP product, unless in the opinion of the Investigator and Sponsor, the medication would not interfere with the study outcomes or compromise subject safety.
• Subject unable to abstain from consumption of tryptophan-rich foods 48 hours prior to admission to the clinic through the Follow-up visit
• Consumption of grapefruit or Seville oranges or their juices within the 7 days prior to dosing until collection of the final PK sample.
• Use of medications associated with QT prolongation within 30 days prior to dosing and during the study. A list of prohibited medications is provided in an appendix to the protocol.
• Subjects unable to abstain from alcohol for 72 hours prior to the start of dosing through collection of their final PK sample
• Subjects with a clinical history of or current alcohol abuse defined as an average weekly intake of more than 21 units for males or 15 units for females (1 unit = 340 mL beer, 115 mL wine, or 43 mL spirits).
• Subjects with a clinical history of or current illicit drug use which, in the opinion of the Investigator, would interfere with the subject's ability to complete the study and could compromise subject safety and/or the results of the study.
• Subjects unable to abstain from caffeine, xanthine, or strenuous exercise for 72 hours prior to dosing until collection of their final PK sample.
• Subjects who have smoked or used tobacco or nicotine-containing products or cannabidiol and related products (in all forms) within 3 months prior to the Screening visit and who are unwilling to refrain from cannabidiol and related products, smoking, tobacco use, or use of nicotine products and all for the entire duration of the study (through the Follow-up visit)
• History of hypersensitivity to rodatristat ethyl, any its components, or any components in the placebo preparation.
• Employed as site personnel directly involved with this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rodatristat Ethyl 300 mg BID - Japanese subjects	Drug: Rodatristat Ethyl 300 mg BID; Tablets, oral, 300 mg, BID 14 days
Placebo Comparator: Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects	Drug: Placebo; Tablets, oral, 0 mg, BID for 14 days
Experimental: Rodatristat Ethyl 300 mg BID - Caucasian subjects	Drug: Rodatristat Ethyl 300 mg BID; Tablets, oral, 300 mg, BID 14 days
Placebo Comparator: Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects	Drug: Placebo; Tablets, oral, 0 mg, BID for 14 days
Experimental: Rodatristat Ethyl 600 mg BID - Japanese subjects	Drug: Rodatristat Ethyl 600 mg BID; Tablets, oral, 600 mg, BID 14 days
Placebo Comparator: Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects	Drug: Placebo; Tablets, oral, 0 mg, BID for 14 days
Experimental: Rodatristat Ethyl 600 mg BID - Caucasian subjects	Drug: Rodatristat Ethyl 600 mg BID; Tablets, oral, 600 mg, BID 14 days
Placebo Comparator: Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects	Drug: Placebo; Tablets, oral, 0 mg, BID for 14 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of rodatristat ethyl by incidence of adverse events	Assessments of adverse events	21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Single dose AUC(0-∞)	Single dose area under the concentration time curve from time zero (predose-) extrapolated to infinity (AUC(0-∞)) of rodatristat ethyl and metabolite(s).	21 days
Single dose AUC(0-t)	Single dose area under the concentration time curve from time zero to the last detectable time point (AUC(0-t)) of rodatristat ethyl and metabolite(s).	21 days
Single dose Cmax	Single dose maximum observed concentration (Cmax) of rodatristat ethyl and metabolite(s).	21 days
Single dose tmax	Single dose time to maximum concentration (tmax) of rodatristat ethyl and metabolite(s).	21 days
Single dose t½	Single dose elimination half-life (t½) of rodatristat ethyl and metabolite(s).	21 days
Steady state tmax	Steady-state tmax of rodatristat ethyl and metabolite(s).	21 days
Steady state Cmax	Steady-state Cmax of rodatristat ethyl and metabolite(s).	21 days
Steady state Cτ	Steady-state concentration at end of dosing interval (Cτ) of rodatristat ethyl and metabolite(s).	21 days
Steady state Cavg	Steady-state average concentration at steady state (Cavg) of rodatristat ethyl and metabolite(s).	21 days
Steady state AUC(0-τ)	Steady-state area under the concentration-time curve over the dosing interval at steady-state (AUC(0-τ)) of rodatristat ethyl and metabolite(s).	21 days
Steady state t½	Steady-state t½ of rodatristat ethyl and metabolite(s).	21 days
Pharmacodynamic assessment - change from baseline in 5-HIAA concentrations	PD as assessed by the change from baseline in 5-hydroxyindoleacedtic acid (5-HIAA) concentrations (plasma and 24-hour urinary excretion)	21 days

Collaborators and Investigators

• Sponsor: Altavant Sciences GmbH
• Collaborators: Parexel; Altavant Sciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2021
• Primary Completion (Actual): March 30, 2022
• Study Completion (Actual): March 30, 2022

Study Registration Dates

• First Submitted: August 2, 2021
• First Submitted That Met QC Criteria: September 22, 2021
• First Posted (Actual): October 4, 2021

Study Record Updates

• Last Update Posted (Actual): July 13, 2022
• Last Update Submitted That Met QC Criteria: July 11, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Pulmonary Arterial Hypertension; PAH
• Other Study ID Numbers: RVT-1201-1005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No